The U.S. Supreme Court is set to decide on a contentious resolution to the opioid crisis, potentially granting the Sackler family immunity from legal action. This decision could shape future negotiations in similar scenarios, affecting corporations and their executives.
Initial approval of a $6 billion settlement was granted in May 2023 by a New York court, only to be challenged by the U.S. Trustee Program, a branch of the U.S. Department of Justice. The hearing at the Supreme Court is scheduled for Monday.
Purdue Pharma, owned and operated by the deceased brothers Mortimer and Raymond Sackler's family, argues they are not released from liability if the family does not receive the $6 billion settlement. However, the U.S. Trustee argues such an agreement would be unprecedented.
The Supreme Court case revolves around the fate of a company that played a significant role in the early days of the opioid crisis, which claimed countless lives. Thousands of Americans advocate for another chance to hold the Sackler family accountable in court.
Understanding the Settlement Deal
The controversial proposal involves the Sacklers paying up to $6 billion over an 18-year period to aid in fighting the ongoing opioid epidemic. Most of the money goes to state, local governments, and Native American tribes.
The agreement also includes $700 to $750 million for individual victim and family compensation. Purdue Pharma claims this is the only significant opioid settlement offering "meaningful recovery" to victims.
If the deal is approved, Purdue Pharma will cease to exist, and a new company, Knoa Pharma, will be established. Knoa will focus on developing opioid addiction treatments and medications for opioid overdose antidotes while continuing to manufacture Purdue's products, including OxyContin.
As part of the deal, Sackler family members receive immunity from all civil (but not criminal) lawsuits.
Attorneys for Purdue Pharma argue that exempting Sackler family members from other claims prevents depleting the assets allocated for the settlement.
Historical Supreme Court Cases
When the insolvency plan was provisionally approved in May, all 50 U.S. states either supported or remained silent on the matter. The Sackler family expressed satisfaction with the decision.
However, the U.S. Trustee appealed to the Supreme Court for review, arguing that the deal constitutes an abuse of the insolvency system.
Experts question the Court's likely decision. They consider this one of the largest insolvency cases the Court has handled in decades, not only due to national interest in the opioid crisis but also due to the question of whether insolvency judges can protect Sackler family members from future consequences of their past actions.
The Enduring Opioid Epidemic
Purdue Pharma introduced OxyContin, an opioid painkiller, in the 1990s. The company and its founder were accused of fueling the opioid crisis in the U.S. by aggressively marketing OxyContin as a safer and less addictive pain relief option and encouraging doctors to prescribe it long-term.
Despite a 2007 confession from a Purdue Frederick subsidiary of mislabeling the drug, additional lawsuits surfaced. Some claim that the Sackler family knew of OxyContin's addictive nature but still promoted it.
As the opioid crisis worsened, attention shifted to Purdue Pharma's and the Sackler family's role.
The Supreme Court hearing is scheduled for Monday, potentially setting a new precedent in the battle against the opioid crisis.
